Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Unmasked, Non-randomized Study Evaluating the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) That is Relapsing or Refractory to Other Treatments, and in Older Patients With ALL for Whom Conventional Treatments Are Not Recommended

NCT03742323 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT03742323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03742323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Unmasked, Non-randomized Study Evaluating the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) That is Relapsing or Refractory to Other Treatments, and in Older Patients With ALL for Whom Conventional Treatments Are Not Recommended
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Terminated
Start date
July 1, 2018
Completion date
June 2, 2020
Enrollment
6 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia